title: Effect of topiramate on the kainate-induced status epilepticus, lipid peroxidation and immunoreactivity of rats.
abstract: Topiramate, a new anticonvulsant, has been reported to possess neuroprotective effects in both in vivo and in vitro experiments. In the present study, the effect of topiramate (40 and 80 mg/kg ip) on the fully developed kainate-induced status epilepticus was evaluated in the rat. Injection of kainate (15 mg/kg ip) evoked recurrent limbic seizures which lasted several hours. Topiramate injected 1.5 h after kainate administration had no effect on the seizures and mortality of the animals. Biochemical study revealed that at 80 mg/kg ip, topiramate significantly attenuated the kainate-induced lipid peroxidation in the piriform cortex and showed similar tendency in the frontal cortex. Besides the central nervous system, the kainate-induced seizures evoked significant changes in immunoreactivity, such as reduction in thymus weight and the proliferative activity of splenocytes, and the splenocyte-increased production of interleukin-10, but not interferon-gamma. Topiramate did not affect the kainate-induced reduction in thymus weight, but attenuated changes in the proliferative activity of splenocytes. It is concluded that topiramate, when given during the fully developed kainate-induced status epilepticus in rats, has no effect on seizures, but attenuates lipid peroxidation in piriform cortex and prevents certain changes in immunoactivity.
authors.affiliation: Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, PL 31-343 Kraków, Poland.
authors.forename: M
authors.initials: M
authors.lastname: Kubera
authors.forename: B
authors.initials: B
authors.lastname: Budziszewska
authors.forename: L
authors.initials: L
authors.lastname: Jaworska-Feil
authors.forename: A
authors.initials: A
authors.lastname: Basta-Kaim
authors.forename: M
authors.initials: M
authors.lastname: Leśkiewicz
authors.forename: M
authors.initials: M
authors.lastname: Tetich
authors.forename: M
authors.initials: M
authors.lastname: Maes
authors.forename: G
authors.initials: G
authors.lastname: Kenis
authors.forename: A
authors.initials: A
authors.lastname: Marciniak
authors.forename: S J
authors.initials: SJ
authors.lastname: Czuczwar
authors.forename: G
authors.initials: G
authors.lastname: Jagła
authors.forename: W
authors.initials: W
authors.lastname: Nowak
authors.forename: W
authors.initials: W
authors.lastname: Lasoń
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D005632:Fructose / Q000031:analogs & derivatives* / Q000494:pharmacology*; D007608:Kainic Acid / Q000633:toxicity; D015227:Lipid Peroxidation / Q000187:drug effects* / Q000502:physiology; D008297:Male; D009929:Organ Size / Q000187:drug effects / Q000276:immunology; D051381:Rats; D017208:Rats, Wistar; D013154:Spleen / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D013226:Status Epilepticus / Q000139:chemically induced / Q000276:immunology* / Q000378:metabolism* / Q000503:physiopathology; D013950:Thymus Gland / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D000077236:Topiramate
chemical_list: D000077236:Topiramate; D005632:Fructose; D007608:Kainic Acid